Sodium–Glucose CoTransporter-2 Inhibitor Empagliflozin Ameliorates Sunitinib-Induced Cardiac Dysfunction via Regulation of AMPK–mTOR Signaling Pathway–Mediated Autophagy

Background: Sodium–glucose cotransporter-2 (SGLT2) inhibitors have been shown to decrease the adverse cardiac events and risks of cardiovascular mortality among patients with or without diabetes, which has made these drugs promising treatment options for patients with chronic heart failure. Cardiac...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Changzhen, Sun, Kaiqiang, Zhang, Yanda, Hu, Yangxi, Hu, Bowen, Zhao, Jian, He, Zhiqing, Ding, Ru, Wang, Weizhong, Liang, Chun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8116890/
https://www.ncbi.nlm.nih.gov/pubmed/33995090
http://dx.doi.org/10.3389/fphar.2021.664181

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8116890/
https://www.ncbi.nlm.nih.gov/pubmed/33995090
http://dx.doi.org/10.3389/fphar.2021.664181

Ejemplares similares